Ibrutinib (Imbruvica®) is accepted for restricted use within NHS Scotland for treatment of Waldenström's macroglobulinaemia

A phase III study found progression-free survival was longer in patients who received ibrutinib plus rituximab compared with placebo plus rituximab in a phase III studyApproval is restricted to patients who have received at least one prior therapy.

Source:

Scottish Medicines Consortium